Adicet Bio Inc (ACET)vsNovartis AG ADR (NVS)
ACET
Adicet Bio Inc
$7.63
-0.52%
HEALTHCARE · Cap: $73.22M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $280.79B
Smart Verdict
WallStSmart Research — data-driven comparison
NVS leads profitability with a 24.7% profit margin vs 0.0%. ACET appears more attractively valued with a PEG of 0.82. NVS earns a higher WallStSmart Score of 51/100 (C-).
ACET
Hold40
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACET.
Margin of Safety
-52.2%
Fair Value
$109.78
Current Price
$147.85
$38.07 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Growing faster than its price suggests
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 27.8%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
2.2% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 11.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : ACET
The strongest argument for ACET centers on Price/Book, PEG Ratio. PEG of 0.82 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.
Bear Case : ACET
The primary concerns for ACET are EPS Growth, Market Cap, Profit Margin.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.
Key Dynamics to Monitor
ACET carries more volatility with a beta of 1.58 — expect wider price swings.
NVS is growing revenue faster at 2.2% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 40/100), backed by strong 24.7% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adicet Bio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company is headquartered in Boston, Massachusetts.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?